US EditionSwitching From a Compounded to a Brand-Name GLP-1? Here’s How to Do It in 5 Steps
- A large meta-analysis presented at ERA 2025 evaluated GLP-1 receptor agonists' effects on kidney outcomes using data through December 2024.
- The analysis included 19 randomized controlled trials with over 90,000 patients averaging 60.77 years to assess composite renal outcomes primarily in diabetic populations.
- Results showed GLP-1 RAs reduced composite renal outcomes by 19%, improved eGFR slope, and lowered microalbuminuria, also showing cardiovascular and mortality benefits.
- The relative risk for composite renal outcomes was 0.81 , microalbuminuria reduced by 24%, and no significant increase in serious adverse events occurred.
- Investigators concluded GLP-1 RAs offer renal and cardiovascular benefits but require more trials, especially in non-diabetic patients and broader populations, to confirm findings.
11 Articles
11 Articles
Santa New Mexican
Switching from a compounded to a brand-name GLP-1? Here’s how to do it in 5 steps
GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make the process of switching from a compounded GLP-1 to a brand-name GLP-1 smoother, safer, and more affordable.
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
In this Review, the possibilities for utilizing GLP-1 receptor agonists in individualized treatment for type 2 diabetes mellitus are discussed. The currently available compounds are evaluated in terms of their efficacy, duration of action and adverse effects. The feasibility of selecting a treatment option on the basis of an individual's clinical parameters and requirements is also touched upon. In healthy humans, the incretin glucagon-like pept…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
